企業プロフィール
DexCom, Inc. 株価・ニュース・カタリスト
- ティッカー:
- DXCM
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
86.23 USD (-0.07%)
終値
最終更新: 2026年10月1日
28.3B USD
時価総額
株価変動の要因
2026年10月1日 時点で DXCM の株価は小幅な動きにとどまり、$86.23 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Glucose Biosensing Company
Dexcom develops continuous glucose monitoring systems that help people measure and manage glucose without relying only on intermittent finger-stick tests. Its products serve people with diabetes as well as consumers seeking broader metabolic-health insights.
Prescription CGM Franchise
The Dexcom G7 platform provides real-time glucose readings, alerts, trend information, and connectivity to compatible mobile devices and insulin-delivery systems. The franchise is used across intensive insulin therapy, basal insulin, and expanding populations with type 2 diabetes.
Stelo Consumer Platform
Stelo is an over-the-counter glucose biosensor and app designed for adults who do not use insulin. It extends Dexcom into direct-to-consumer distribution and combines glucose data with food logging, behavioral insights, and AI-enabled interpretation.
Clinical Evidence and Market Expansion
Dexcom invests in randomized studies such as CONNECT to demonstrate the value of continuous glucose monitoring in less intensively treated populations. Evidence generation supports payer coverage, clinical guidelines, and adoption among primary-care clinicians and people with type 2 diabetes.
Connected Diabetes Ecosystem
The company integrates its sensors with insulin pumps, connected pens, digital health applications, and clinical data platforms. These partnerships make Dexcom's data a core component of automated insulin delivery and remote diabetes management.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。